
Transcription-replication conflicts underlie sensitivity to PARP inhibitors in cancer therapy.


coremsg

Poly(ADP-ribose) polymerase 1 (PARP1) functions together with TIMELESS and TIPIN to protect the replisome in early S phase from transcription–replication conflicts, and inhibiting PARP1 enzymatic activity may suffice for treatment efficacy in homologous recombination-deficient settings.

Transcription–replication conflicts underlie sensitivity to PARP inhibitors - Nature

understanding-sensitivity-to-parp-inhibitors-in-cancer-therapy


Understanding Sensitivity to PARP Inhibitors in Cancer Therapy
